GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Foresee Pharmaceuticals Co Ltd (ROCO:6576) » Definitions » YoY EBITDA Growth

Foresee Pharmaceuticals Co (ROCO:6576) YoY EBITDA Growth : -42.06% (As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Foresee Pharmaceuticals Co YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Foresee Pharmaceuticals Co's YoY EBITDA Growth for the quarter that ended in Dec. 2024 was -42.06%.

Foresee Pharmaceuticals Co's EBITDA per Share for the three months ended in Dec. 2024 was NT$-3.24.


Foresee Pharmaceuticals Co YoY EBITDA Growth Historical Data

The historical data trend for Foresee Pharmaceuticals Co's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Foresee Pharmaceuticals Co YoY EBITDA Growth Chart

Foresee Pharmaceuticals Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.96 4.91 18.31 -118.91 3.88

Foresee Pharmaceuticals Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -42.32 51.19 54.20 -68.70 -42.06

Foresee Pharmaceuticals Co YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Foresee Pharmaceuticals Co's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (A: Dec. 2024 )
=(EBITDA per Share (A: Dec. 2024 )-EBITDA per Share (A: Dec. 2023 ))/ | EBITDA per Share (A: Dec. 2023 ) |
=(-6.889--7.167)/ | -7.167 |
=3.88 %

Foresee Pharmaceuticals Co's YoY EBITDA Growth for the quarter that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (Q: Dec. 2024 )
=(EBITDA per Share (Q: Dec. 2024 )-EBITDA per Share (Q: Dec. 2023 )) / | EBITDA per Share (Q: Dec. 2023 )) |
=(-3.239--2.28)/ | -2.28 |
=-42.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Foresee Pharmaceuticals Co YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Foresee Pharmaceuticals Co's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Foresee Pharmaceuticals Co Business Description

Traded in Other Exchanges
N/A
Address
No. 19-3, Sanchong Road, 9th Floor-2, Nangang District, Taipei, TWN, 115
Foresee Pharmaceuticals Co Ltd is engaged in the development and commercialization of new drugs using its proprietary drug delivery technology. Its main activity is to apply its Stabilized injectable formulation(SIF) platform technology to produce the products for anticancer and treatment of chronic disease. Its SIF product pipeline includes FP-001 for prostate cancer, FP-004 for Opioid drug addiction/Pain, FP-011 for Breast Cancer/Prostate Cancer, FP-016 for neurological diseases, and others. All of its revenue is generated from Taiwan.

Foresee Pharmaceuticals Co Headlines

No Headlines